Skip to content

Motion Sickness Desensitization Using VR

Evaluation and Countermeasures of Motion Sickness by Virtual Reality Desensitization Protocol

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05628220
Acronym
SENSORIEL1
Enrollment
30
Registered
2022-11-28
Start date
2018-01-10
Completion date
2023-02-28
Last updated
2022-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Motion Sickness

Keywords

vestibular system, posture, anxiety, nausea, motion sickness, visually induced motion sickness

Brief summary

Evaluation of a virtual reality desensitization protocol on subjects with severe motion sickness and study of the role of the emotional component on the effectiveness of the therapy.

Detailed description

Motion sickness is a well-known syndrome, particularly at risk in children, with a maximum around the age of 12. All people are sensitive to motion sickness in childhood, probably related to the maturation of certain cognitive functions of a spatial nature, namely the perception of oneself and one's movements in one's environment. These symptoms regress with age for a part of the population but a large number of people will remain sensitive to certain conditions of displacement and generate symptoms that can be extremely disabling and handicapping in everyday life, particularly for professional activities. For example, some people can no longer use their car, some can no longer take the boat for professional activities in restrictive and/or extreme environments (sailors, scientists, workers, etc.). Behavioral, respiratory or medicinal therapies remain partially effective due to the lack of sufficient knowledge on the physiopathology of this syndrome classified in the field of sensory disorders. Very recently, techniques of sensory desensitization by visual stimulation have appeared, either optokinetic or in virtual reality mimicking the environment that causes this syndrome. This therapeutic approach seems to give empirically good results but only one study has shown it with optokinetic stimulation but it is to be evaluated for virtual reality. The main objective of the study is therefore to evaluate the effectiveness of a sensory conflict protocol generated in virtual reality to reduce the severity of motion sickness. Each subject being his own control. An observational study was then designed to quantify the effectiveness of this technique carried out in a current way by the physiotherapists in the form of questionnaires supplemented by a posturographic evaluation of the sensory profile of the subjects. If the effectiveness is proven, this desensitization protocol could be optimized and more widely distributed. Furthermore, the analysis of the visuo-dependence variable (from the sensory profile) will indicate whether the use of a visual stimulus by virtual reality alone is sufficient or should be combined or compared with desensitization of other sensory modalities. The use of galvanic vestibular stimulation for the rehabilitation of vestibular pathologies or training programs based on the resolution of sensory conflicts could be envisaged in the future.

Interventions

OTHERphysiotherapy

rehabilitation through using session of virtual reality desensitization

Sponsors

University Hospital, Caen
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

one cohort of patients suffering from motion sickness

Eligibility

Sex/Gender
ALL
Age
18 Years to 67 Years
Healthy volunteers
No

Inclusion criteria

* Suffering from motion sickness inducing a functional disability requiring a change in the mode of travel, or suffering from motion sickness disabling to exercise a leisure or professional activity involving a mode of locomotion.

Exclusion criteria

* Pregnant woman * History of severe ENT or ophthalmologic pathologies. * Chronic treatment with an anticholinergic or anti-histamine medication. * Participating in another biomedical research protocol during the same period * Person under guardianship or curatorship

Design outcomes

Primary

MeasureTime frameDescription
motion sickness severityday 0 (day before the first session of rehabilitation)simulator sickness questionnaire (0-64)

Secondary

MeasureTime frameDescription
Emotionday 0 (day before the first session of rehabilitation)The State-Trait Anxiety Questionnaire (0-80)
Postureday 0 (day before the first session of rehabilitation)postural measurement (gravity center ellipse)

Countries

France

Contacts

Primary Contactstephane besnard, MD, PhD
stephane.besnard@unicaen.fr+33677978649

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026